The present invention relates generally to medical treatment systems, and more particularly, to reduced-pressure wound treatment systems.
Physicians perform millions of surgical procedures each year around the world. Many of the procedures are performed as open surgery and an increasing number are performed using minimally invasive surgery, such as endoscopic, arthroscopic, and laparoscopic procedures. As one example, the American Society for Aesthetic Plastic Surgery reports that there were more than 450,000 liposuction procedures in the United States in 2007.
Surgical procedures involve acute wounds, e.g., an incision, in the skin and related tissue. In many instances, the incision is closed at the conclusion of the procedure using a mechanical apparatus, such as staples or suture, or closed using adhesives. Thereafter, the wound is often merely covered with a dry, sterile bandage. Of course, there is usually more disruption than just at the epidermis.
With many surgical procedures, particularly those done with minimally invasive techniques, much of the disruption or damage is below the epidermis, or at a subcutaneous level. Again, as one example, in one type of liposuction procedure, after the introduction of a tumescent fluid (saline, mild painkiller, and epinephrine), the surgeon will use a trocar and cannula with suction to remove fatty areas. In doing so, it is not uncommon to have subcutaneous voids and other tissue defects formed at tissue sites remote from the incision through which the cannula was placed or other incisions through which equipment was placed. The damaged tissue will need time and care to heal and poses a number of potential complications and risks including edema, seroma, hematoma, further bruising, and ecchymosis to name some.
According to one illustrative embodiment, a system for providing a force to a desired treatment area on a curved body part of a person includes a dressing assembly for placing on the desired treatment area of the person. The dressing assembly has a longitudinal portion with a first end and a second end. The dressing assembly also includes an interior surface member having a first surface and a second, inward-facing surface and a dressing bolster having a first surface and a second, inward-facing surface. The second, inward-facing surface of the dressing bolster is disposed against the first surface of the interior surface member. The system further includes a releaseable circumferential member coupled to the first end and second end of the dressing assembly, a sealing subsystem for providing a fluid seal over the dressing assembly, and a reduced-pressure subsystem for providing a reduced pressure to the dressing assembly.
According to one illustrative embodiment, a system for providing a force to a desired treatment area on a curved body part of a person includes a dressing assembly for placing on the desired treatment area of the person. The dressing assembly has a longitudinal portion with a first end and a second end. The dressing assembly includes a first material having a first surface and a second, inward-facing surface and a second material having a first surface and a second, inward-facing surface. The second, inward-facing surface of the first material is disposed against the first surface of the second material. The system further includes a releaseable circumferential member coupled to the first end and second end of the dressing assembly and a reduced-pressure subsystem for providing a reduced pressure to the dressing assembly.
According to one illustrative embodiment, a system for providing a compressive force to a desired treatment area on a person's torso includes a dressing assembly shaped and configured to be placed on at least a portion of the person's torso and a releasable circumferential connector for holding the dressing assembly against the torso. The circumferential connector and the dressing assembly include a circumferential member. The system further includes a sealing subsystem for providing a fluid seal over the dressing assembly and the person's epidermis and a reduced-pressure subsystem for providing reduced pressure to the dressing assembly whereupon the system is operable to generate a compressive force against at least a portion of the torso.
According to one illustrative embodiment, a system for providing a compressive force to a desired treatment area on a person's torso includes a dressing assembly for placing on the desired treatment area of the person. The dressing assembly includes a longitudinal portion with a first end and a second end, and a dressing bolster having a first surface and a second, inward-facing surface. The second, inward-facing surface of the dressing bolster is disposed against the first surface of the interior surface member. The dressing assembly further includes an envelope member surrounding the dressing bolster. The envelope member includes an interior surface member having a first surface and a second, inward-facing surface, and an exterior surface member having a first surface and a second, inward-facing surface. The second, inward-facing surface of the exterior surface member is disposed proximate the first surface of the dressing bolster. The dressing bolster is formed from a bolster material having a density greater than 25 kg/m3. the system further includes a releaseable circumferential member coupled to the first end and second end of the dressing assembly and a sealing subsystem for providing a fluid seal over the dressing assembly and the person's epidermis. The sealing subsystem includes an over-drape that extends over the exterior surface member, and a sealing apparatus for providing a fluid seal over a person's epidermis and the over-drape.
According to one illustrative embodiment, a method of manufacturing a system for providing a compressive force to a desired treatment area on a curved body part of a person includes the step of forming a dressing assembly shaped and configured to be placed on the desired treatment area of the person. The method further includes providing a releasable circumferential connector for holding the dressing assembly against the desired treatment area and providing a sealing subsystem for providing a fluid seal over the dressing assembly and the person's epidermis.
According to one illustrative embodiment, a method of providing a force to at least a portion of a curved body part of a person includes the steps of: deploying a dressing assembly on the curved body part. The dressing assembly includes an interior surface member for placing over the desired treatment area and having a first surface and a second, inward-facing surface and a dressing bolster having a first surface and a second, inward-facing surface. The second, inward-facing surface of the dressing bolster is disposed against the first surface of the interior surface member thereby sealing the dressing assembly to the curved body part. The method further includes providing reduced pressure to the dressing assembly. The dressing bolster has a first volume (V1) at ambient pressure and a second volume (V2) when under reduced pressure and V1>V2.
According to one illustrative embodiment, a method for providing a force to a curved body part includes the step of: placing a dressing assembly against a desired area. The dressing assembly has a longitudinal portion with a first end and a second end. The method further includes releseably coupling the first end to the second end to hold the longitudinal portion of the dressing assembly against the patient in the desired treatment area; fluidly coupling a reduced-pressure source to the dressing assembly; and activating the reduced pressure source to provide reduced pressure to the dressing assembly. The dressing assembly is placed, under reduced pressure and contracts to form a directed force.
Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and the detailed description that follow.
A more complete understanding of the present invention may be obtained by reference to the following Detailed Description when taken in conjunction with the accompanying Drawings wherein:
In the following detailed description of illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.
Referring to
The system 2 allows support to be given to a portion of a person's body with relative ease, and the system 2 allows various sizes of body parts to be accommodated by a single system or apparatus thereby reducing the need for large inventories. When used with a wound, the system 2 may keep the wound dry, reduce dead space formation, improve perfusion, reduce seroma and hematoma formation, and reduce bruising and edema secondary to certain surgical procedures. The system 2 also provides comparative comfort for the patient or person using the system 2. The force developed by system 2 may be varied by varying the reduced pressure delivered to the system 2, and a feedback loop may be used to allow automated adjustments of reduced pressure to maintain a desired compressive force on a treatment site even as swelling increases or decreases.
Referring now to
The incision 12 may be closed using any closing device such as staples, sutures, or adhesive, but is shown in this illustrative embodiment with a suture 13. The system 10 typically is for treating an area and, in particular, is typically for treating a subcutaneous tissue site 20 and the tissue around subcutaneous tissue 20, but the system 10 may also be used to treat the more limited area of the incision 12.
The system 10 includes a dressing assembly 30, which includes a shaped dressing bolster 32 (or dressing bolster), a sealing subsystem 60, and a reduced-pressure subsystem 80. The system 10 develops a net compressive force, represented by reference numerals 24, that is realized at the subcutaneous tissue 20. As described further below, the shaped dressing bolster 32 may be shaped and configured to allow the compressive force 24 to be distributed fairly evenly over the patient's epidermis 14 and beneath the epidermis 14. Otherwise, if there are areas of substantially increased force as compared to other areas, skin irritation may result. The system 10 may also be operable to develop an inward force (or closing force), i.e. towards an interior portion of dressing assembly 30. The inward force is represented by reference numerals 26. The inward force 26 may remain substantially within the plane of the epidermis 14. In other words, the inward force 26 operates mainly within the epidermis 14. In addition, the system 10 is operable to deliver reduced pressure to the incision 12. The reduced pressure may be realized at the level of the subcutaneous void 22 to help approximate—bring together—the tissues in that region as well as to help remove any air or any other fluids, e.g., exudates.
The dressing assembly 30 includes the shaped dressing bolster 32, which has a first side 34 and a second, inward (tissue-facing) side 36. The shaped dressing bolster 32 may be sized and shaped to substantially match the estimated area of undermined subcutaneous tissue 20 although a larger or smaller size may be used. The shaped dressing bolster 32 has a peripheral edge 38. The shaped dressing bolster 32 may be made of a number of different bolster materials. In one illustrative embodiment, the shaped dressing bolster 32 is made from a porous and permeable foam-like material and, more particularly, a reticulated, open-cell polyurethane or polyether foam that allows good permeability of wound fluids while under a reduced pressure. One such foam material that has been used is the VAC® Granufoam® material that is available from Kinetic Concepts, Inc. (KCI) of San Antonio, Tex. Any material or combination of materials might be used for the bolster material provided that the bolster material is operable to distribute the reduced pressure and provide the desired forces.
The shaped dressing bolster 32 may be a manifold that is sized and shaped to distribute forces evenly and to distribute reduced pressure. The term “manifold” as used herein generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site. The manifold typically includes a plurality of flow channels or pathways that are interconnected to improve distribution of fluids provided to and removed from the tissue site around the manifold. The manifold may be a biocompatible material that is capable of being placed in contact with the tissue site and distributing reduced pressure to the tissue site. Examples of manifolds may include, for example, without limitation, devices that have structural elements arranged to form flow channels, such as, for example, cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. The manifold may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. Other embodiments might include “closed cells.” In some situations, the manifold may also be used to distribute fluids such as medications, antibacterials, growth factors, and various solutions to the tissue site. Other layers may be included in or on the manifold, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.
The reticulated pores of the Granufoam® material, that are in the range from about 400 to 600 microns, are helpful in carrying out the manifolding function, but other materials may be used. The density of the medical bolster material, e.g., Granufoam® material, is typically in the range of about 1.3 lb/ft3-1.6 lb/ft3 (20.8 kg/m3-25.6 kg/m3). A material with a higher density (smaller pore size) than Granufoam® material may be desirable in some situations. For example, the Granufoam® material or similar material with a density greater than 1.6 lb/ft3 (25.6 kg/m3) may be used. As another example, the Granufoam® material or similar material with a density greater than 2.0 lb/ft3 (32 kg/m3) or 5.0 lb/ft3 (80.1 kg/m3) or even more may be used. The more dense the material is, the higher compressive force that may be generated for a given reduced pressure. If a foam with a density less than the tissue at the tissue site is used as the medical bolster material, a lifting force may be developed. In one illustrative embodiment, a portion, e.g., the edges, of the dressing assembly may exert a compressive force while another portion, e.g., a central portion, may provide a lifting force.
The bolster material may be a reticulated foam that is later felted to thickness of about one third (⅓) of the foam's original thickness. Among the many possible bolster materials, the following may be used: Granufoam® material or a Foamex® technical foam (www.foamex.com). In some instances it may be desirable to add ionic silver to the foam in a microbonding process or to add other substances to the bolster material such as antimicrobial agents. The bolster material may be isotropic or anisotropic depending on the exact orientation of the compressive forces 24 that are desired during the application of reduced pressure. The bolster material may also be a bio-absorbable material.
The sealing subsystem 60 includes an over-drape 62 (drape) or sealing member. The over-drape 62 may be an elastomeric material or may be any material that provides a fluid seal. “Fluid seal,” or “seal,” means a seal adequate to hold reduced pressure at a desired site given the particular reduced-pressure subsystem involved. “Elastomeric” means having the properties of an elastomer and generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have elongation rates greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. As non-limiting examples, the over-drape 62 may be formed from materials that include a silicone, 3M Tegaderm® drape material, acrylic drape material such as one available from Avery, or an incise drape material.
The over-drape 62 may be coupled to the bolster 32. The coupling may occur in many ways. The over-drape 62 and the bolster 32 may be coupled using adhesives such as an acrylic adhesive, silicone adhesive, hydrogel, hydrocolloid, etc. The over-drape 62 and the bolster 32 might be bonded by heat bonding, ultrasonic bonding, and radio frequency bonding, etc. The coupling may occur in discrete patterns or more completely. Structural members might be added to the bond to make the over-drape 62 behave anisotropically in a desired direction, i.e. to make an anisotropic drape material. An anisotropic drape material helps the dressing assembly 30 to primarily move in a given direction, i.e. only about a certain axis or axes.
In the illustrative embodiment of
The reduced-pressure subsystem 80 includes a reduced-pressure source 82, which can take many different forms. The reduced-pressure source 82 provides a reduced pressure as a part of the system 10. The reduced-pressure source 82 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, or other source. While the amount and nature of reduced pressure applied to a tissue site and shaped dressing bolster 32 will typically vary according to the application, the reduced pressure will typically be between −5 mm Hg an −500 mm Hg and more typically between −100 mm Hg and −300 mm Hg.
As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced pressure delivered may be constant or varied (patterned or random) and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure.
In order to maximize patient mobility and ease, the reduced-pressure source 82 may be a battery-powered, single-use reduced-pressure generator. Such a reduced-pressure source 82 facilitates application in the operating room and provides mobility and convenience for the patient during the rehabilitation phase. The reduced-pressure source 82 has a battery compartment 84 and a canister region 86 with windows 88 providing a visual indication of the level of fluid within the canister 86. An interposed membrane filter, such as hydrophobic or oleophobic filter, might be interspersed between a reduced-pressure delivery conduit, or tubing, 90 and the reduced-pressure source 82.
For many procedures, it is believed that the patient would be directed to wear the system 10 for three to five days and may be directed to wear system 10 for 15 days or more. Still, the treatment time is a welcomed time period in contrast to treatment with conventional compressive garments, which are worn after many procedures today for up to six weeks. Accordingly, the battery life and/or power provisions may need to accommodate up to 15 days of operation. Other sources of reduced pressure may also be utilized such as V.A.C.® therapy unit, which is available from KCI of San Antonio, Tex., or a wall suction unit. The reduced-pressure source 82 may also be supplied by a portable mechanical device, such as a piston in a tube, depending on how much leakage there is with the fluid seal between the shaped dressing bolster 32 and the epidermis 14.
The reduced pressure developed by the reduced-pressure source 82 is delivered through the reduced-pressure delivery conduit 90 to a reduced-pressure interface 92, which may be an elbow port 94. In one illustrative embodiment, the port 94 is a TRAC® technology port available from KCI of San Antonio, Tex. The reduced-pressure interface 92 allows the reduced pressure to be delivered to the sealing subsystem 60 and realized within an interior portion of the sealing subsystem 60. In this illustrative embodiment, the port 94 extends through the over-drape 62 and into the shaped dressing bolster 32.
In operation, the system 10 may be applied in the operating room after a surgical procedure on the patient or at another time. The second surface 36 of the shaped dressing bolster 32 is placed against the patient's epidermis 14 with the shaped dressing bolster 32 over the undermined subcutaneous tissue site 20 and with a portion over the incision 12. The dressing assembly 30 may be sized for the typical application involved in the procedure performed by a healthcare provider. The dressing assembly 30 may be sized, shaped, and configured to work with different anatomical applications such as abdominal, chest, thighs, arms, etc.
If the over-drape 62 has not already been coupled (see other illustrative embodiments below) to the shaped dressing bolster 32, the over-drape 62 is then placed over the first surface 34 of the shaped dressing bolster 32 with an extra portion extending beyond the peripheral edge 38 to form the drape extension 64. The drape extension 64 can then be taped to the epidermis 14 (see 172 in
As the pressure is reduced at the shaped dressing bolster 32, the shaped dressing bolster 32 compresses and contracts laterally and forms a semi-rigid substrate and, as a result, a number of beneficial forces and actions take place. The reduced pressure is transmitted further still through the shaped dressing bolster 32 so that reduced pressure is experienced at the patient's epidermis 14 at the incision 12. At least at the early stages of the healing process, the reduced pressure is realized through the incision 12 and into the subcutaneous tissue 20 and the reduction of pressure helps close defects, such as subcutaneous void 22, and generally provides stability to the area. The reduced pressure delivered to the shaped dressing bolster 32 also develops the compressive force 24 that again may provide stability and therapy. The compressive force 24 is more than just at the epidermis 14. The compressive force 24 extends down deeper and may be experienced at the level of subcutaneous tissue 20.
As the over-drape 62 and shaped dressing bolster 32 laterally contract under the influence of the reduced pressure, and as the downward force acts through the Poisson's ratio for the epidermis 14, an inward force 26 develops that may help hold a closing force on the incision 12 and may generally provide additional stability to the incision 12 or treatment site. The inward force 26 may rely in part on friction between the shaped dressing bolster 32 and the epidermis 14 to communicate the force to the epidermis 14 and may involve force transmission from the drape extension 64 to the epidermis 14 by way of the adhesive 70 or through friction if tape (172 in
One operational concern is to avoid skin irritation in deploying and using the system 10. Accordingly, care is taken to avoid skin irritation, such as blistering of the patient's epidermis 14, that may be due to secondary shear, secondary strain or other effects. For this reason, the extremity 33 of the shaped dressing bolster 32 may be shaped to provide an even distribution of compressive forces. The extremity 33 is the outer, shaped portion of bolster 32 and the peripheral edge is generally the most outboard portion of the shaped dressing bolster 32 or the most outboard portion that interface with patient's epidermis. The extremity 33 may be a chamfered surface, but other shapes, e.g., an arcuate shape in system 110 (
The shaped edge, or extremity, of the shaped dressing bolster 32 allows a compressive force 24 to be developed without a big “edge effect”; that is, without causing shear or stress to rise to a level that causes skin irritation such as erythema or blistering. The shaped portion gradually distributes the force to avoid irritation. This way of carefully applying the forces to the epidermis 14 to avoid irritation is generally referred to as “evenly distributing” the compressive force 24, but is not strictly used in a literal sense. There may be some variation, but not enough to cause irritation of the epidermis 14. As another precaution against skin irritation, an inner layer might be added between the shaped dressing bolster 32 and the patient's epidermis 14 (see 857 in
It may be desirable to apply the system 10 in the operating room and allow the system 10 to remain on the patient until adequate healing has taken place. In this regard, it may be desirable to form the over-drape 62, the shaped dressing bolster 32, and any other layers from see-through materials to allow the healthcare provider to gain visual cues about the healing of the incision 12 and the undermined subcutaneous tissue 20 without having to remove the dressing assembly 30.
Referring now to
The system 110 includes a dressing assembly 130 having a shaped dressing bolster 132. The shaped dressing bolster 132 has a first side 132 and a second, inward-facing side 136. While the shaped dressing bolster 32 of
The system 110 includes a sealing subsystem 160 to provide a fluid seal over the shaped dressing bolster 132. A reduced-pressure delivery conduit 190 delivers reduced pressure to a reduced-pressure interface 192, e.g., a port 194, that is in fluid communication with an interior portion of the sealing subsystem 160.
In this illustrative embodiment, the ambient pressure provides a force 131 on a first surface 161 of the over-drape 162 and the contraction of the shaped dressing bolster 132 develops a compression force 124 to provide a net force that is experienced down into the skin and that reaches dermis 116 and may reach other subcutaneous levels 118. At the same time, a substantially in-plane force directed inward is developed. The inward force might be developed through two different mechanisms. First, an inward force 127 is an inward contraction force caused by the shaped dressing bolster 132 being compressed and as the shaped dressing bolster 132 compresses the shaped dressing bolster 132 is drawn inward. At the same time, as the reduced pressure is applied, the over-drape 162 is drawn into the area proximate the extremity 133 as suggested by arrow 128. Because a drape extension 164 is secured to the epidermis 114, the horizontal component of the resultant force 128 would pull the epidermis 114 inward as is suggested by the inward force 129.
Referring now to
The reduced-pressure interface 292 delivers the reduced pressure to the shaped dressing bolster 232. As the shaped dressing bolster 232 is compressed under the influence of reduced pressure, a net compressive force 224 is developed that is delivered to the tissue site 220. In this embodiment, an extremity 233 of the shaped dressing bolster 232 is formed with an orthogonal end. The over-drape 262 forms a “tent” area 229 around a void 235. Under reduced pressure, the over-drape 262 is pulled into the void 235 and a force is thereby applied that develops an inward contracting force 226.
In the system 210, the curvature of the shaped dressing bolster 232 also helps develop a compressive force. A first surface 234 of the shaped dressing bolster 232 has a greater surface area than the surface area of a second, inward-facing surface 236 of the shaped dressing bolster 232. Thus, under reduced pressure, this difference in surface areas also facilitates the development of a net compressive force 224.
Referring now to
A dressing bolster 332 is disposed against the epidermis 314 and a drape, or an over-drape 362, is used to form a sealed area containing the dressing bolster 332. Reduced pressure is delivered through a reduced-pressure conduit 390 to a reduced-pressure interface 392. The reduced-pressure interface 392 delivers reduced pressure to the dressing bolster 332. Circumferential forces developed during the application of reduced pressure combine in the system 310 to develop inward compressive forces 324. The compressive forces can be higher than a flat or partial-torso application because there is no off-loading of force to the drape and to the skin.
Referring now to
As shown clearly in
The dressing bolster 432 may be made from any of the bolster materials described elsewhere in this application. The dressing bolster 432 may include bolster material that is not uniform throughout since one may want the dressing bolster 432 to be more rigid (and not provide as much lift) in some places or one may want the dressing bolster 432 to be less rigid and to develop maximum lift in some places, e.g., like at the breasts on the brassiere embodiment below. The bolster material may be made more or less rigid using a bolster material with varying properties or using two or more different materials that are combined to form the bolster material. In some applications, it may be desirable to form the bolster material from a honeycomb material such as a Supracor® fusion-bonded honeycomb material from Supracor Systems, Inc. of Sunnyvale, Calif.
The dressing assembly 430 may further include an exterior surface member 446, or exterior member, which has a first side 448 and a second side 450. The interior surface member 440, or interior member, and the exterior surface member 446 may be made with a pre-tensioned elastic material such as a spandex material; for example, a Lycra® brand material might be used. The interior surface member 440 has high contractibility to avoid wrinkling, which would result in contact loading against the skin. Furthermore, the low friction of the material used for the inner surface member 440 helps to reduce the possibility of shear injury to the epidermis. Moreover, the permeability of the inner surface member 440, or layer, results in reduced-pressure transmission to the tissue site and provides a pathway for exudate removal. The interior surface member 440, or interior member, and the exterior surface member 446 may be coupled to form an envelope surrounding the dressing bolster 432.
The second side 450 of the exterior surface member 446 may be coupled to the first surface 434 of the dressing bolster 432. The coupling of the various members (e.g., surface 436 to surface 442 and surface 450 to 434) may occur in many ways; a number of examples follow. One might use adhesives such as acrylic adhesive, silicone adhesive, hydrogel, hydrocolloid, etc. or might use bonding such as heat bonding, ultrasonic bonding, or radio frequency bonding, etc. The coupling may occur in patterns or may cover the whole. Structural members may be added to the coupling to make the member behave anisotropically in a desired direction. In addition, struts or other mechanical elements may be supplied within the bolster to change the compression and characteristics of the dressing bolster 432.
The dressing assembly 430 is shown in
The dressing bolster 432 and any additional layers such as the interior surface member 440 and the exterior surface member 446 may be covered with an over-drape 462, which is part of a sealing subsystem 460. The over-drape 462 may extend beyond peripheral edges 438 and 439 to form drape extension 464, which has a first side 466 and a second side 468. A fluid seal may be formed between the drape extension 464 and the patient's epidermis 414 by using a sealing apparatus 469, such as a sealing tape, or drape tape 471, an adhesive (see adhesive 5 in
The sealing subsystem 460 provides a fluid seal, or otherwise allows the system 410 to maintain reduced pressure at the desired treatment site 412. The sealing subsystem 460 preferably includes the over-drape 462 and the sealing apparatus 469. While described as forming a fluid seal, there may in fact be some leakage and the resultant small air leaks actually provide a low velocity airflow throughout the dressing assembly 430 that is distributed and helps to remove moisture. In an alternative embodiment, instead of using the over-drape 462, the exterior surface member 446 may be made to have an airtight exterior portion and drape tape may be directed to cover the edges of the bolster material as well an other portions that are not otherwise sealed.
A reduced-pressure subsystem 480 is shown in part and is analogous to the reduced-pressure subsystems of previously presented embodiments, e.g., 80 of
As shown clearly in
A portion of the joining elements 454 may include fasteners 456, which may be a hook and loop fastener, clasps, or other means of connecting two portions of the joining elements 454. The joining elements 454 and fasteners 456 form a circumferential connector and with the dressing assembly 430 complete a path around the curved body part or form a completed, releasable circumferential member 458. Thus, the releasable circumferential member 458 extends around the patient's torso 404 to allow the releasable circumferential member 458 to be held against the torso 404 and, in particular, holds bolster 432 against the desired treatment area 412 even before the reduced pressure is delivered by the reduced-pressure subsystem 480. Additional drape tape may be used to provide a fluid seal over the joining elements 454 and fasteners 456.
The transition area 452 may include a first end 453 and a second end 455 of the dressing assembly 430 and in particular the ends of a longitudinal portion 457 that is shown surrounding the patient's torso 404. The two ends are thus brought together and releaseably held by the releasable circumferential member 458, which includes the joining elements 454 and fasteners 456.
The differences in surface areas of the first surface 434 and second surface 436 of the dressing bolster 432 contributes to the production of a net compressive (inward) force. The net compressive force increases linearly with the increase in the ratio of the circumference of the first surface 434 of the dressing bolster 432 to the second surface 436 of the dressing bolster 432. Thus, to have a greater compression developed, the dressing bolster 432 may be made thicker to increase the ratio. The bending stiffness of the dressing bolster 432 may also influence the delivery of the developed compression force. The net compressive force is distributed fairly uniformly if the dressing 430 has a low-bending stiffness. With reference briefly to
Returning now to
Referring now to
Referring to
The system 610 includes a dressing assembly 630, which includes a dressing bolster 632 having a first surface 634 and a second, inward-facing surface 636. The dressing assembly 630 may include an interior surface member 638 having a first surface 640 and a second, inward-facing surface 642. The interior surface member 638 may be coupled on a first surface 640 to the second surface 636 of the dressing bolster 632. The dressing assembly 630 may also include an exterior surface member 644, which has a first surface 646 and a second, inward-facing surface 648. The exterior surface member 644 may be coupled on a second surface to the first surface 634 of the bolster 632.
A sealing subsystem 660 provides a fluid seal sufficient to maintain a reduced pressure against the patient's epidermis in the desired support area 618 when under a reduced pressure from a reduced-pressure subsystem 680. The sealing subsystem 660 may take a number of different forms. The present embodiment includes an over-drape 662 that covers the dressing bolster 632 and may extend beyond peripheral edges 650 of the dressing bolster 632 to form extensions 664 to which a sealing apparatus 667 may be applied to form the fluid seal with the epidermis. The sealing apparatus 667 may take numerous forms such as adhesive, a sealing tape 668 or strip, double-sided sealing tape, paste, hydrocolloid, hydrogel, or other sealing means. The sealing apparatus 667 might also involve additional elements as shown in
Referring now to
Referring now to
Referring now primarily to
The therapeutic brassiere 612 might be bifurcated to have separate bolsters with separate sealing subsystems for each breast cup 682, 684 so that different pressure levels can be supplied to each breast cup 682, 684 to accommodate different sizes or situations. For example, if one breast has been the subject of a mastectomy and the other has not, different reduced pressures may be desired.
Referring now primarily to
In operation, the system 610 is utilized by placing the therapeutic brassiere 612 on the torso 604 so that at least a portion of the bolster 632 is proximate the breast tissue 614, and preferably proximate the support area 618. The dressing assembly 630 along with the joining element 654 and fasteners 656 form a releasable circumferential connector 698 that holds the therapeutic brassiere 612 in place even before the reduced pressure from the reduced-pressure subsystem 680 is applied. Once the therapeutic brassier 612 is in place, the reduced-pressure subsystem 680 is activated and reduced pressure is delivered through the reduced-pressure interface 692 to the dressing bolster 632. The dressing bolster 632 collapses and contracts under the influence of the reduced pressure and thereby causes tension to develop throughout the circumferential connector 698 and provides a compression force and an element of a supporting (upward) force to the support area 618 or to the breast tissue 614.
The systems and apparatuses have been shown applied on various body parts, e.g., abdomen and breast, but other applications are included. For example, the system may be used on a thigh of a person in which case the bolster assembly might be held in place by a pair of shorts similar to biking shorts. As another example, the systems and apparatuses described for breast tissue might be modified to form a large single front cup that could be used to lift and support a pannus or other hanging flap of tissue. As still one more example, a reduced-pressure cup made in a analogous style to that presented for the breast tissue could be used for testicular support after surgery and might be incorporated into shorts.
According to another illustrative embodiment, a method of providing a force to at least a portion of a curved body part of a person includes the step of deploying a dressing assembly on the curved body part. The dressing assembly includes an interior surface member for placing over the desired treatment area and having a first surface and a second, inward-facing surface. The dressing bolster has a first surface and a second, inward-facing surface. The second, inward-facing surface of the dressing bolster is disposed against the first surface of the interior surface member. The dressing assembly may be sealed to the curved body part. The method further includes providing reduced pressure to the dressing assembly. When reduced pressure is applied, the dressing bolster goes from a first volume (V1) at ambient pressure to a second volume (V2) at reduced pressure. In other words, the first volume is greater than the second: V1>V2. As the volume changes, a directed force is developed that may include a compressive portion, a lifting portion, or a inward closing portion.
Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in a connection to any one embodiment may also be applicable to any other embodiment.
The present invention is a continuation of U.S. patent application Ser. No. 12/475,301, entitled “REDUCED-PRESSURE, COMPRESSION SYSTEMS AND APPARATUSES FOR USE ON A CURVED BODY PART,” filed May 29, 2009 now U.S. Pat. No. 8,129,580, which claims the benefit, under 35 USC §119(e), of the filing of U.S. Provisional Patent Application Ser. No. 61/057,807, entitled “REDUCED-PRESSURE SURGICAL WOUND TREATMENT SYSTEM,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,798, entitled “DRESSING ASSEMBLY FOR SUBCUTANEOUS WOUND TREATMENT USING REDUCE PRESSURE,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,808, entitled “SEE-THROUGH, REDUCED-PRESSURE DRESSING,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,802, entitled “REDUCED-PRESSURE DRESSING ASSEMBLY FOR USE IN APPLYING A CLOSING FORCE,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057, 803, entitled “REDUCED-PRESSURE, LINEAR-WOUND TREATMENT SYSTEM,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,800, entitled “REDUCED-PRESSURE, COMPRESSION SYSTEM AND APPARATUS FOR USE ON A CURVED BODY PART,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,797, entitled “REDUCED-PRESSURE, COMPRESSION SYSTEM AND APPARATUS FOR USE ON BREAST TISSUE,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,805, entitled “SUPER-ABSORBENT, REDUCED-PRESSURE WOUND DRESSING AND SYSTEM,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/057,810, entitled “REDUCED-PRESSURE, COMPRESSION SYSTEM AND APPARATUS FOR USE ON A JOINT,” filed May 30, 2008; U.S. Provisional Patent Application Ser. No. 61/121,362, entitled “REDUCED-PRESSURE WOUND TREATMENT SYSTEM EMPLOYING AN ANISOTROPIC DRAPE,” filed Dec. 10, 2008; and U.S. Provisional Patent Application Ser. No. 61/144,067, entitled “REDUCED-PRESSURE, COMPRESSION SYSTEM AND APPARATUS FOR USE ON A JOINT,” filed Jan. 12, 2009. All of the patent applications listed in this paragraph are hereby incorporated by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
1195430 | Angier | Aug 1916 | A |
1355846 | Rannells | Oct 1920 | A |
1845630 | Scholl | Feb 1932 | A |
2452345 | Anselmo | Oct 1948 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3026874 | Stevens | Mar 1962 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3419006 | King | Dec 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
3892229 | Taylor et al. | Jul 1975 | A |
4080970 | Miller | Mar 1978 | A |
4091804 | Hasty | May 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4224945 | Cohen | Sep 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4266545 | Moss | May 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4375217 | Arkans | Mar 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielson | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4722332 | Saggers | Feb 1988 | A |
4727868 | Szycher et al. | Mar 1988 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4770490 | Gruenewald et al. | Sep 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4902565 | Brook | Feb 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4917112 | Kalt | Apr 1990 | A |
4919654 | Kalt et al. | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5000741 | Kalt | Mar 1991 | A |
5018515 | Gilman | May 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106629 | Cartmell et al. | Apr 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5160315 | Hienecke et al. | Nov 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5380294 | Persson | Jan 1995 | A |
5423737 | Cartmell et al. | Jun 1995 | A |
5429593 | Matory | Jul 1995 | A |
5435009 | Schild et al. | Jul 1995 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5489262 | Cartmell et al. | Feb 1996 | A |
5497788 | Inman et al. | Mar 1996 | A |
5520629 | Heinecke et al. | May 1996 | A |
5527293 | Zamierowski | Jun 1996 | A |
5538502 | Johnstone | Jul 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5628230 | Flam | May 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5653244 | Shaw | Aug 1997 | A |
5792088 | Felder et al. | Aug 1998 | A |
5844013 | Kenndoff et al. | Dec 1998 | A |
5866249 | Yarusso et al. | Feb 1999 | A |
5950238 | Klein | Sep 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6086450 | Mankovitz | Jul 2000 | A |
6109267 | Shaw et al. | Aug 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6162960 | Klein | Dec 2000 | A |
6213840 | Han | Apr 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6270910 | Jaeger et al. | Aug 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6361397 | Mankovitz et al. | Mar 2002 | B1 |
6420622 | Johnston et al. | Jul 2002 | B1 |
6440093 | McEwen et al. | Aug 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6648862 | Watson | Nov 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6867342 | Johnston et al. | Mar 2005 | B2 |
D503509 | Bell et al. | Apr 2005 | S |
6936037 | Bubb et al. | Aug 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7090647 | Mimura et al. | Aug 2006 | B2 |
7135007 | Scott et al. | Nov 2006 | B2 |
7144294 | Bell et al. | Dec 2006 | B2 |
7195624 | Lockwood et al. | Mar 2007 | B2 |
7201063 | Taylor | Apr 2007 | B2 |
7201263 | Osada et al. | Apr 2007 | B2 |
7214202 | Vogel et al. | May 2007 | B1 |
7316672 | Hunt et al. | Jan 2008 | B1 |
7361184 | Joshi | Apr 2008 | B2 |
7455681 | Wilke et al. | Nov 2008 | B2 |
7504549 | Castellani et al. | Mar 2009 | B2 |
7520872 | Biggie et al. | Apr 2009 | B2 |
7532953 | Vogel | May 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7699831 | Bengtson et al. | Apr 2010 | B2 |
8100848 | Wilkes et al. | Jan 2012 | B2 |
20010029956 | Argenta et al. | Oct 2001 | A1 |
20010043943 | Coffey | Nov 2001 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20030040691 | Griesbach et al. | Feb 2003 | A1 |
20030109816 | Lachenbruch et al. | Jun 2003 | A1 |
20030212359 | Butler | Nov 2003 | A1 |
20040039415 | Zamierowski | Feb 2004 | A1 |
20040064111 | Lockwood et al. | Apr 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040242119 | Francis | Dec 2004 | A1 |
20040243073 | Lockwood et al. | Dec 2004 | A1 |
20050209574 | Boehringer et al. | Sep 2005 | A1 |
20050222544 | Weston | Oct 2005 | A1 |
20050228329 | Boehringer et al. | Oct 2005 | A1 |
20060041247 | Petrosenko et al. | Feb 2006 | A1 |
20060064049 | Marcsen | Mar 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060149171 | Vogel et al. | Jul 2006 | A1 |
20060173253 | Ganapathy | Aug 2006 | A1 |
20060189910 | Johnson et al. | Aug 2006 | A1 |
20060213527 | Argenta et al. | Sep 2006 | A1 |
20060264796 | Flick et al. | Nov 2006 | A1 |
20070021697 | Ginther et al. | Jan 2007 | A1 |
20070027414 | Hoffman et al. | Feb 2007 | A1 |
20070066946 | Haggstrom et al. | Mar 2007 | A1 |
20070078366 | Haggstrom et al. | Apr 2007 | A1 |
20070135777 | Greene et al. | Jun 2007 | A1 |
20070167884 | Mangrum | Jul 2007 | A1 |
20070185426 | Ambrosio | Aug 2007 | A1 |
20070219497 | Johnson | Sep 2007 | A1 |
20070219513 | Lina et al. | Sep 2007 | A1 |
20070219532 | Karpowicz et al. | Sep 2007 | A1 |
20080004549 | Anderson et al. | Jan 2008 | A1 |
20080009812 | Riesinger | Jan 2008 | A1 |
20080039763 | Sigurjonsson et al. | Feb 2008 | A1 |
20080076844 | Van Sumeren et al. | Mar 2008 | A1 |
20080103462 | Wenzel | May 2008 | A1 |
20080119802 | Riesinger | May 2008 | A1 |
20090043268 | Eddy et al. | Feb 2009 | A1 |
20090177051 | Arons et al. | Jul 2009 | A1 |
20090204084 | Blott et al. | Aug 2009 | A1 |
20090204085 | Biggie et al. | Aug 2009 | A1 |
20090227968 | Vess | Sep 2009 | A1 |
20090234307 | Vitaris | Sep 2009 | A1 |
20090264807 | Haggstrom | Oct 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
755496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
39 07 522 | Apr 1990 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
20 2006 007877 | Jul 2006 | DE |
10 2005 007016 | Aug 2006 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0330373 | Aug 1989 | EP |
0358302 | Mar 1990 | EP |
0424165 | Apr 1991 | EP |
0691113 | Jan 1996 | EP |
1018967 | Aug 2004 | EP |
1163907 | Oct 1958 | FR |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
4129536 | Apr 1992 | JP |
H105356 | Jan 1998 | JP |
2000210386 | Aug 2000 | JP |
2006239213 | Sep 2006 | JP |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 9010424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9514451 | Jun 1995 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Mar 1999 | WO |
WO 0007653 | Feb 2000 | WO |
WO 03057071 | Jul 2003 | WO |
WO 03057307 | Jul 2003 | WO |
WO 03086262 | Oct 2003 | WO |
WO03101385 | Nov 2003 | WO |
WO 2005123170 | Dec 2005 | WO |
WO 2006012745 | Feb 2006 | WO |
WO 2007031762 | Mar 2007 | WO |
WO 2007033679 | Mar 2007 | WO |
WO 2007041642 | Apr 2007 | WO |
WO 2008054312 | May 2008 | WO |
WO 2008063281 | May 2008 | WO |
WO 2009019496 | Feb 2009 | WO |
WO 2009047524 | Apr 2009 | WO |
WO 2009071926 | Jun 2009 | WO |
Entry |
---|
Response filed Jan. 19, 2012 for U.S. Appl. No. 12/475,380. |
Interview Summary date mailed Jan. 25, 2012 for U.S. Appl. No. 12/475,380. |
Notice of Allowance date mailed Feb. 15, 2012 for U.S. Appl. No. 12/475,380. |
Response filed Feb. 9, 2012 for U.S. Appl. No. 12/475,328. |
Notice of Allowance date mailed Feb. 17, 2012 for U.S. Appl. No. 12/475,388. |
Notice of Allowance date mailed Jan. 20, 2012 for U.S. Appl. No. 12/475,231. |
Notice of Allowance date mailed Jan. 10, 2012 for U.S. Appl. No. 12/475,373. |
Non-Final Office Action date mailed Dec. 28, 2011 for U.S. Appl. No. 12/475,285. |
Non-Final Office Action date mailed Nov. 8, 2011 for U.S. Appl. No. 12/475,380. |
Response filed Nov. 22, 2011 for U.S. Appl. No. 12/475,398. |
Interview Summary date mailed Nov. 29, 2011 for U.S. Appl. No. 12/475,398. |
Notice of Allowance date mailed Nov. 14, 2011 for U.S. Appl. No. 12/475,301. |
Notice of Allowance date mailed Jan. 3, 2012 for U.S. Appl. No. 12/475,319. |
Non-Final Office Action date mailed Dec. 9, 2011 for U.S. Appl. No. 12/475,328. |
Response filed Nov. 11, 2011 for U.S. Appl. No. 12/475,388. |
Interview Summary date mailed Dec. 5, 2011 for U.S. Appl. No. 12/475,388. |
Response filed Nov. 11, 2011 for U.S. Appl. No. 12/475,231. |
Interview Summary date mailed Dec. 5, 2011 for U.S. Appl. No. 12/475,231. |
Notice of Allowance date mailed Jan. 9, 2012 for U.S. Appl. No. 12/475,407. |
Richard S. Laskin, et al “Minimally Invasive Total Knee Replacement Through a Mini-Midvast Incision: An Outcome Study” Surgical Technology International XIII, 2004; 231-8. |
A. Dee, “The successful management of a dehisced surgical wound with TNP following femoropopliteal bypass”, Journal of Wound Care, vol. 16, No. 1, Jan. 2007. |
Ogazon, e of Vacuum-Assisted Closure in the Treatment of Surgical Infection Sites Cir. Mar.-Apr. 2006; 74(2): 107-13 Spanish. |
Timmenga, “The Effects of Mechanical Stress on Healing Skin Wounds: An Experimental Study in Rabbits ing Tissues Expansions,” British Journal of Plastic Surgery 1991; 44(7): 514-519. |
Cunningham, “Development of in-vitro model to simulate Dermal Wound Bed Interaction with GranuFoam and Gauze Dressing under Sub Atmospheric Pressure,” RPT 111-05-02, device implant innovations 2006. |
Delalleau, “Characterization of the Mechanical Properties of Skin by Inverse Analysis Combined with the Indentation Test” Journal of Biomechanics 39 (2006) 1603-1610. |
Pailler-Mattei, “Study of Adhesion Forces and Mechanical Properties of Human Skin in vivo” J. Adhesion Sci. Technol., vol. 18, No. 15-16, pp. 1739-1758 (2004). |
Khatyr, “Model of the Viscoelastic Behaviour of Skin in vivo and Study of Anisotropy,” Skin Research and Technology 2004; 10:96-103. |
Wilkes, “3D Strain Measurement in Soft Tissue: Demonstration of a Novel Inverse Finite Element Model Algorithm on MicroCT Images of a Tissue Phantom Exposed to Negative Pressure Wound Therapy,” Journal of the Mechanical Behaviour of Biomedical Materials (2008), pp. 1-16. |
Diridollou, “In vivo Model of the Mechanical Properties of the Human Skin under Suction”, Skin Research and Technology, 2000; 6:214-221. |
Woo, “Structural Model to Describe the Non-Linear Stress-Strain Behavior for Parallel-Fibered Collageno Tissues,” Journal of Biomechanical Engineering, Nov. 1989, vol. 111/361. |
International Search Report and Written Opinion date mailed Oct. 20, 20009; PCT International Application No. PCT/2009/045747. |
International Search Report and Written Opinion date mailed Oct. 16, 2009; PCT International Application No. PCT/2009/045752. |
Partial International Search Report and Written Opinion date mailed Oct. 7, 2009; PCT International Application No. PCT/2009/045755. |
Internatioanl Search Report and Written Opinion date mailed Mar. 12, 2010; PCT International Application No. PCT/2009/045755. |
International Search Report and Written Opinion date mailed Oct. 26, 2009; PCT International Application No. PCT/2009/045751. |
International Search Report and Written Opinion date mailed Oct. 14, 2009; PCT International Application No. PCT/2009/045746. |
International Search Report and Written Opinion date mailed Oct. 27, 2009; PCT International Application No. PCT/2009/045744. |
Partial International Search Report and Written Opinion date mailed Oct. 19, 2009; PCT Internatioanl Application No. PCT/2009/045742. |
Partial International Search Report and Written Opinion date mailed Nov. 2, 2009; PCT International Application No. PCT/2009/045750. |
International Search Report and Written Opinion date mailed Oct. 21, 2009; PCT International Application No. PCT/2009/045749. |
International Search Report and Written Opinion date mailed Nov. 11, 2009; PCT International Application No. PCT/2009/045754. |
International Search Report and Written Opinion date mailed Dec. 11, 2009; PCT International Application No. PCT/2009/045753. |
International Search Report and Written Opinion date mailed Feb. 25, 2010; PCT International Application No. PCT/2009/045750. |
International Search Report for PCT International Application No. PCT/2009/045743 date mailed Aug. 20, 2009. |
Product Information for OptSite™ dressing, viewed Aug. 14, 2011. |
International Search Report for PCT International Application No. PCT/US2011/034300 date mailed Aug. 30, 2011. |
Non-Final Rejection mailed Jul. 20, 2011 for U.S. Appl. No. 12/475,301. |
Response filed Oct. 5, 2011 for U.S. Appl. No. 12/475,301. |
Restriction Requirement mailed Aug. 16, 2011 for U.S. Appl. No. 12/475,380. |
Response filed Sep. 13, 2011 for U.S. Appl. No. 12/475,380. |
Restriction Requirement mailed May 10, 2011 for U.S. Appl. No. 12/475,285. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,285. |
Non-Final Rejection mailed Aug. 19, 2011 for U.S. Appl. No. 12/475,285. |
Response filed Oct. 20, 2011 for U.S. Appl. No. 12/475,285. |
Interview Summary date mailed Oct. 26, 2011 for U.S. Appl. No. 12/475,285. |
Restriction Requirement mailed May 10, 2011 for U.S. Appl. No. 12/475,367. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,367. |
Non-Final Rejection mailed Aug. 23, 2011 for U.S. Appl. No. 12/475,367. |
Response filed Oct. 18, 2011 for U.S. Appl. No. 12/475,367. |
Restriction Requirement mailed May 17, 2011 for U.S. Appl. No. 12/475,319. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,319. |
Non-Final Rejection mailed Aug. 18, 2011 for U.S. Appl. No. 12/475,319. |
Response filed Oct. 20, 2011 for U.S. Appl. No. 12/475,319. |
Interview Summary date mailed Oct. 26, 2011 for U.S. Appl. No. 12/475,319. |
Non-Final Rejection mailed May 24, 2011 for U.S. Appl. No. 12/475,257. |
Response to Non-Final Rejection filed Jul. 27, 2011 for U.S. Appl. No. 12/475,257. |
Notice of Allowance mailed Sep. 16, 2011 for U.S. Appl. No. 12/475,257. |
Restriction Requirement mailed May 9, 2011 for U.S. Appl. No. 12/475,388. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,388. |
Non-Final Rejection mailed Sep. 7, 2011 for U.S. Appl. No. 12/475,388. |
Restriction Requirement mailed Apr. 29, 2011 for U.S. Appl. No. 12/475,231. |
Response filed May 19, 2011 for U.S. Appl. No. 12/475,231. |
Non-Final Rejection mailed Sep. 6, 2011 for U.S. Appl. No. 12/475,231. |
Restriction Requirement mailed May 12, 2011 for U.S. Appl. No. 12/475,407. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,407. |
Non-Final Rejection mailed Aug. 23, 2011 for U.S. Appl. No. 12/475,407. |
Response filed Oct. 20, 2011 for U.S. Appl. No. 12/475,407. |
Interview Summary date mailed Oct. 27, 2011 for U.S. Appl. No. 12/475,407. |
Restriction Requirement mailed May 9, 2011 for U.S. Appl. No. 12/475,373. |
Response filed Jun. 7, 2011 for U.S. Appl. No. 12/475,373. |
Non-Final Rejection mailed Aug. 23, 2011 for U.S. Appl. No. 12/475,373. |
Response filed Oct. 25, 2011 for U.S. Appl. No. 12/475,373. |
Interview Summary date mailed Oct. 27, 2011 for U.S. Appl. No. 12/475,373. |
Non-Final Office Action date mailed Sep. 15, 2011 for U.S. Appl. No. 12/475,398. |
Restriction Requirement date mailed Oct. 12, 2011 for U.S. Appl. No. 12/475,328. |
Response filed Oct. 19, 2011 for U.S. Appl. No. 12/475,328. |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (certified translation). |
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997. |
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinović, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007). |
Number | Date | Country | |
---|---|---|---|
20120029487 A1 | Feb 2012 | US |
Number | Date | Country | |
---|---|---|---|
61057807 | May 2008 | US | |
61057798 | May 2008 | US | |
61057808 | May 2008 | US | |
61057802 | May 2008 | US | |
61057803 | May 2008 | US | |
61057800 | May 2008 | US | |
61057797 | May 2008 | US | |
61057805 | May 2008 | US | |
61057810 | May 2008 | US | |
61121362 | Dec 2008 | US | |
61144067 | Jan 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12475301 | May 2009 | US |
Child | 13253711 | US |